 BEDFORD, Mass.--BUSINESS WIRE--- OCUL OCUTX--Ocular Therapeutix, Inc. NASDAQ:OCUL, a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced the U.S. Food and Drug Administration FDA has approved its Supplemental New Drug Application sNDA to broaden the DEXTENZA label to add an additional indication for the treatment of ocular itching associated with allergic conjunctivitis. With the appro 